Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

14 trials with published results (9%)

Research Maturity

79 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.5%

9 terminated out of 164 trials

Success Rate

89.8%

+3.2% vs benchmark

Late-Stage Pipeline

10%

17 trials in Phase 3/4

Results Transparency

18%

14 of 79 completed with results

Key Signals

14 with results90% success

Data Visualizations

Phase Distribution

104Total
Not Applicable (36)
Early P 1 (6)
P 1 (20)
P 2 (25)
P 3 (7)
P 4 (10)

Trial Status

Completed79
Recruiting31
Unknown20
Not Yet Recruiting10
Active Not Recruiting9
Terminated9

Trial Success Rate

89.8%

Benchmark: 86.5%

Based on 79 completed trials

Clinical Trials (164)

Showing 20 of 20 trials
NCT06741969Phase 3Active Not RecruitingPrimary

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT07732582Not ApplicableNot Yet RecruitingPrimary

Sjogren's Mini-Pill Oral and Gut Microbiome Study

NCT02327884Recruiting

Characterization of Diseases With Salivary Gland Involvement

NCT01425892RecruitingPrimary

The Pathogenesis and Natural History of Sjogren's Disease

NCT07712939Phase 1Recruiting

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

NCT07180537Not ApplicableRecruiting

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT07281456Phase 2RecruitingPrimary

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT05985915Phase 3Active Not RecruitingPrimary

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT04931160Not ApplicableRecruitingPrimary

B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome

NCT06410742CompletedPrimary

Comprehensive Evaluation of Clinical and Biopsychosocial Characteristics in Primary Sjögren's Disease

NCT05961267Completed

Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism

NCT03841318Not ApplicableCompletedPrimary

Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome

NCT06312020Phase 2TerminatedPrimary

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

NCT05644795Not ApplicableCompletedPrimary

Wheat-free Diet in the Treatment of Sjogren's Syndrome

NCT05879419Phase 4Active Not Recruiting

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases

NCT03711214Not ApplicableActive Not RecruitingPrimary

Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome

NCT06437652CompletedPrimary

An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome

NCT03157011Not ApplicableCompletedPrimary

Evaluation of the Prevalence of Functional Digestive Disorders During Primary Sjögren Gougerot Syndrome

NCT02370225Not ApplicableCompletedPrimary

Aerobic Exercise in Primary Sjögren's Syndrome

NCT07041099Phase 1Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Scroll to load more

Research Network

Activity Timeline